AI Article Synopsis

  • Traditional assessment of movement quality in patients with spinocerebellar ataxia relies on subjective scales, making it difficult to detect subtle mobility changes; hence, researchers explored using machine learning to enhance assessment.
  • The study involved a phase 3 trial comparing the effects of the drug troriluzole versus a placebo on gait quality, measured through video analysis and a new stability metric called the Pose Dispersion Index.
  • Results showed that those taking troriluzole had significant improvements in the tandem walk stability measure after 48 weeks, while a trend in natural walking improvement was also noted, and lower scores in baseline stability were linked to a higher fall risk.

Article Abstract

Introduction: Traditional methods for assessing movement quality rely on subjective standardized scales and clinical expertise. This limitation creates challenges for assessing patients with spinocerebellar ataxia (SCA), in whom changes in mobility can be subtle and varied. We hypothesized that a machine learning analytic system might complement traditional clinician-rated measures of gait. Our objective was to use a video-based assessment of gait dispersion to compare the effects of troriluzole with placebo on gait quality in adults with SCA.

Methods: Participants with SCA underwent gait assessment in a phase 3, double-blind, placebo-controlled trial of troriluzole (NCT03701399). Videos were processed through a deep learning pose extraction algorithm, followed by the estimation of a novel gait stability measure, the Pose Dispersion Index, quantifying the frame-by-frame symmetry, balance, and stability during natural and tandem walk tasks. The effects of troriluzole treatment were assessed in mixed linear models, participant-level grouping, and treatment group-by-visit week interaction adjusted for age, sex, baseline modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA), and time since diagnosis.

Results: From 218 randomized participants, 67 and 56 participants had interpretable videos of a tandem and natural walk attempt, respectively. At Week 48, individuals assigned to troriluzole exhibited significant (p = 0.010) improvement in tandem walk Pose Dispersion Index versus placebo {adjusted interaction coefficient: 0.584 [95% confidence interval (CI) 0.137 to 1.031]}. A similar, nonsignificant trend was observed in the natural walk assessment [coefficient: 1.198 (95% CI - 1.067 to 3.462)]. Further, lower baseline Pose Dispersion Index during the natural walk was significantly (p = 0.041) associated with a higher risk of subsequent falls [adjusted Poisson coefficient: - 0.356 [95% CI - 0.697 to - 0.014)].

Conclusion: Using this novel approach, troriluzole-treated subjects demonstrated improvement in gait as compared to placebo for the tandem walk. Machine learning applied to video-captured gait parameters can complement clinician-reported motor assessment in adults with SCA. The Pose Dispersion Index may enhance assessment in future research. TRIAL REGISTRATION-CLINICALTRIALS.

Gov Identifier: NCT03701399.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263303PMC
http://dx.doi.org/10.1007/s40120-024-00625-6DOI Listing

Publication Analysis

Top Keywords

pose dispersion
16
tandem walk
12
natural walk
12
movement quality
8
trial troriluzole
8
spinocerebellar ataxia
8
machine learning
8
effects troriluzole
8
gait
7
assessment
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!